ConductScience.org, home

Paper8353095

Low-dose oral etoposide in epithelial cancer of the ovary.

Marzola M and 7 others. Ann Oncol, 1993. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Low-dose oral etoposide in epithelial cancer of the ovary. Papers, record 8353095. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8353095

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Low-dose oral etoposide in epithelial cancer of the ovary.
PubMed
Journal
Ann Oncol
PubMed
Year
1993
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.14
iCite
Revised in PubMed
2020-02-03
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marzola MM
2Zucchetti MM
3Colombo NN
4Sessa CC
5Pagani OO
6D'Incalci MM
7Cavalli FF
8Mangioni CC

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
EtoposideMajor topic
Ovarian NeoplasmsMajor topic
Administration, Oral
Adult
Aged
Biological Availability
Female
Humans
Middle Aged
Neutropenia
Remission Induction
Salvage Therapy

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
15756278Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.Br J Cancer2005https://conductscience.org/library/papers/15756278PubMed
15139794Pharmacokinetic optimisation of treatment with oral etoposide.Clin Pharmacokinet2004https://conductscience.org/library/papers/15139794PubMed
12448655Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study.Invest New Drugs2002https://conductscience.org/library/papers/12448655PubMed
11857002Weekly platinum chemotherapy for recurrent ovarian cancer.Br J Cancer2002https://conductscience.org/library/papers/11857002PubMed
11122800Salvage therapy for ovarian cancer.Curr Oncol Rep1999https://conductscience.org/library/papers/11122800PubMed
10711841Oral etoposide for the treatment of recurrent ovarian cancer.Drugs1999https://conductscience.org/library/papers/10711841PubMed
8286205Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.Br J Cancer1994https://conductscience.org/library/papers/8286205PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8353095

GET https://conductscience.org/api/papers/v1/8353095/authors